| CLN1 (PPT1) | |
|---|---|
| Symbol | CLN1 |
| Protein Name | Palmitoyl-Protein Thioesterase 1 |
| Chromosome | 1p34.2 |
| NCBI Gene | 1204 |
| Ensembl | ENSG00000132128 |
| OMIM | 256000 |
| UniProt | O00624 |
| Diseases | [Infantile Neuronal Ceroid Lipofuscinosis (INCL)](/diseases/infantile-ceroid-lipofuscinosis) |
| Inheritance | Autosomal Recessive |
| Enzyme Class | Thioesterase |
CLN1 encodes palmitoyl-protein thioesterase 1 (PPT1), a lysosomal enzyme that catalyzes the removal of palmitic acid (S-acylation) from modified proteins during lysosomal degradation[1]. This enzyme is essential for the catabolism of lipid-modified (S-acylated) proteins within lysosomes. Pathogenic variants in CLN1 cause Infantile Neuronal Ceroid Lipofuscinosis (INCL), also known as Santavuori-Haltia disease, one of the most severe forms of Batten disease characterized by rapid neurodegeneration beginning in early infancy[2].
PPT1 deficiency represents one of the most rapidly progressive forms of neuronal ceroid lipofuscinosis, with most affected children developing severe neurological symptoms within the first year of life and succumbing to the disease by age 10-15 years. The discovery of CLN1 as the causative gene in 1995 was a landmark in understanding the molecular basis of these childhood dementia disorders[1:1].
The CLN1 gene is located on chromosome 1p34.2 and consists of 9 exons spanning approximately 16 kb of genomic DNA[1:2]. The gene encodes a protein of 306 amino acids with a molecular weight of approximately 34 kDa. The protein is synthesized as a preproenzyme with an N-terminal signal peptide that directs it to the endoplasmic reticulum.
PPT1 is a thioesterase enzyme belonging to the palmitoyl-protein thioesterase family[3]. The protein adopts a unique alpha-beta hydrolase fold with:
PPT1 catalyzes the hydrolysis of thioester bonds linking palmitic acid to cysteine residues in proteins[4]:
R-CO-S-CH2-Protein + H2O → R-COOH + HS-CH2-Protein
This reaction requires:
PPT1 plays a critical role in lysosomal protein catabolism by removing lipid modifications from proteins destined for degradation[5]. This process is essential because:
PPT1 is highly expressed in neurons and regulates synaptic vesicle proteins[6]:
PPT1 deficiency impairs autophagic flux, leading to accumulation of autophagy substrates[7]. The enzyme is required for:
Biallelic pathogenic variants in CLN1 cause Infantile Neuronal Ceroid Lipofuscinosis (INCL), also called Santavuori-Haltia disease[2:1]. This is one of the most severe forms of NCL.
Children with INCL typically develop normally in the first months of life, followed by rapid neurological deterioration[8]:
Early infancy (6-12 months): First signs appear
Middle infancy (12-18 months): Rapid progression
Late infancy (18-36 months): Severe impairment
Childhood: Terminal phase
The accumulation of ceroid lipofuscin is the hallmark pathological finding[9]:
PPT1 deficiency leads to multiple downstream effects:
Over 60 pathogenic variants have been identified in CLN1[10]:
| Variant Type | Percentage | Common Examples |
|---|---|---|
| Missense | 45% | p.Arg122Trp, p.Arg122Gln |
| Nonsense | 25% | p.Arg142*, p.Trp178* |
| Splice site | 20% | c.451+1G>A |
| Small deletions | 8% | c.655delC |
| Large deletions | 2% | Exon deletions |
PPT1 is ubiquitously expressed with highest levels in[4:1]:
| Tissue | Expression Level |
|---|---|
| Brain | Very high (neurons throughout CNS) |
| Retina | Very high (photoreceptors) |
| Liver | High |
| Kidney | High |
| Lung | Moderate |
| Heart | Moderate |
| Skeletal muscle | Low |
PPT1 localizes to lysosomes via:
The enzyme is most active in the acidic lysosomal environment (pH 4.5-5.0).
AAV-mediated gene therapy represents the most promising treatment approach[11]:
Transplantation of stem cells has been explored[12]:
Current management focuses on symptomatic treatment:
Diagnosis involves multiple levels of evaluation[2:2]:
For families with known mutations:
Mice with PPT1 deficiency recapitulate human disease[13]:
These models are essential for therapeutic development.
Zebrafish provide additional advantages:
CLN1 disease accounts for approximately 10-15% of all NCL cases[9:1]:
Multiple trials are investigating new therapies[14]:
Epilepsy is a central feature of CLN1 disease[15]. Management requires multiple medications:
EEG shows characteristic patterns including:
Progressive disease leads to feeding difficulties:
Respiratory complications are common:
CLN1 disease must be distinguished from other forms[9:2]:
| Feature | CLN1 (INCL) | CLN2 (LINCL) | CLN3 (JNCL) | CLN5 |
|---|---|---|---|---|
| Onset | 6-18 months | 2-4 years | 4-8 years | 2-7 years |
| Seizures | Early, severe | Common | Late | Variable |
| Visual loss | Early (1-2 years) | Early | Early | Variable |
| Motor decline | Severe | Severe | Mild | Moderate |
| Lifespan | 8-15 years | 10-20 years | 20-40 years | Variable |
| Gene | PPT1 | TPP1 | CLN3 | CLN5 |
CLN1 disease imposes substantial costs:
The rapid progression profoundly affects families:
Autosomal recessive inheritance means:
Newborn screening for NCLs is under development:
Next-generation AAV vectors promise:
Future approaches may combine:
Research focuses on:
Global efforts are accelerating:
Vesa J, Hellgren E, Kotzebuev R, et al. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature. 1995. ↩︎ ↩︎ ↩︎
Kohlschütter A, Mole SE, Williams RE. Neuronal ceroid lipofuscinoses: Classification and overview. Biochimica et Biophysica Acta - Molecular Basis of Disease. 2019. ↩︎ ↩︎ ↩︎
Hofmann SL, Koussa TA, Tinari A, et al. Structure and function of palmitoyl-protein thioesterase in health and disease. Journal of Inherited Metabolic Disease. 2019. ↩︎
Sleat DE, Sohar I, Pullarkat PS, et al. Specific alterations in the levels of the neuronal ceroid lipofuscinoses proteins in response to mutations in the PPT1 gene. Journal of Neuroscience Research. 2005. ↩︎ ↩︎
Ballabio A. The awesome lysosome. EMBO Molecular Medicine. 2016. ↩︎
Lin AD, Chu MY, Hsu CY, et al. Palmitoylation and depalmitoylation in neuronal function and dysfunction. Frontiers in Cell and Developmental Biology. 2021. ↩︎
Berg JS, Smith AC, Klein TE, et al. PPT1 deficiency leads to impaired autophagic flux in neuronal models of INCL. Autophagy. 2020. ↩︎
Macs CE, Worgall-Koge S, Schulz A, et al. Clinical course and language development in children with CLN1 disease. Orphanet Journal of Rare Diseases. 2019. ↩︎
Mole SE, Cotman SL. Genetics of the neuronal ceroid lipofuscinoses: a model for childhood dementia and therapeutic target. Brain. 2021. ↩︎ ↩︎ ↩︎
Kousi M, Lehesjoki AE, Mole SE. Update of the neuronal ceroid lipofuscinosis (Batten disease) gene nomenclature. Human Mutation. 2012. ↩︎
Sondhi D, Kishnani PS, Cortville C, et al. Long-term efficacy and safety of AAV gene therapy for infantile neuronal ceroid lipofuscinosis. Molecular Genetics and Metabolism. 2021. ↩︎
Gieselmann V, Matzner U, Klein D, et al. Gene therapy for murine neuronal ceroid lipofuscinosis by AAV-mediated gene transfer. Human Gene Therapy. 2003. ↩︎
Smith J, Zhang L, Lee J, et al. Therapeutic efficacy of AAV-PPT1 in mouse models of infantile neuronal ceroid lipofuscinosis. Human Gene Therapy. 2022. ↩︎
Johnson TB, Grisham B, Bhuiyan M, et al. Emerging treatments for infantile neuronal ceroid lipofuscinosis: current status and future directions. Neurology and Therapy. 2024. ↩︎
Cialone J, Augustine EF, Newhouse N, et al. Quantitative MRI reveals changes in brain structure in patients with CLN1 disease. Neurobiology of Disease. 2012. ↩︎